Cancer Investigation最新文献_第2页

Evaluation of Impression Cytology for Diagnosis of Ocular Surface Squamous Neoplasia in Two Kenyan Tertiary Hospitals. 肯尼亚两所三级医院印象细胞学诊断眼表鳞状瘤变的评价。

IF 1.8 4区医学

Cancer Investigation Pub Date : 2025-04-01 Epub Date: 2025-04-15 DOI: 10.1080/07357907.2025.2492031

Chisomo Griffin Phiri, Rhoda M Munene, Stephen Gichuhi, Lucy W Muchiri

{"title":"Evaluation of Impression Cytology for Diagnosis of Ocular Surface Squamous Neoplasia in Two Kenyan Tertiary Hospitals.","authors":"Chisomo Griffin Phiri, Rhoda M Munene, Stephen Gichuhi, Lucy W Muchiri","doi":"10.1080/07357907.2025.2492031","DOIUrl":"10.1080/07357907.2025.2492031","url":null,"abstract":"Introduction: Ocular surface squamous neoplasia (OSSN) is a broad term encompassing pre-cancerous and cancerous conditions affecting the ocular surface. Given the non-specific clinical presentation, there is a need for reliable diagnostic tools that can be used in resource-limited settings. This study assessed the diagnostic accuracy of Impression Cytology (IC) in diagnosing OSSN, compared to histopathology, the gold standard.Methods: A diagnostic accuracy study was conducted involving 40 patients suspected to have OSSN at Kenyatta National Hospital and Kikuyu Hospital. Patients were scheduled for IC followed by surgical excision and Histopathological examination. Sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were calculated.Results: There were 40 participants, 28 females and 12 males, with a mean age of 40.5 years (range 18-70). IC had a sensitivity of 100%, specificity of 82.1%, accuracy of 87.5%, positive predictive value of 70.6%, and negative predictive value of 100%.Conclusion: IC is an effective, minimally invasive diagnostic tool for OSSN, demonstrating high sensitivity and negative predictive value. Its implementation in clinical settings could improve early detection and management of OSSN, particularly in regions with limited access to histopathological services.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"237-243"},"PeriodicalIF":1.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143975204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Capecitabine-Enhanced Brachytherapy in Locally Advanced Cervical Cancer: A Phase II Non-Randomized Trial on Safety and Efficacy. 卡培他滨增强近距离治疗局部晚期宫颈癌：安全性和有效性的II期非随机试验。

IF 1.8 4区医学

Cancer Investigation Pub Date : 2025-04-01 Epub Date: 2025-04-23 DOI: 10.1080/07357907.2025.2493238

Fatemeh Homaei Shandiz, Soudeh Arastouei, Sare Hosseini, Indira Prasad Giri, Seyed Alireza Javadinia, Mahdiye Dayanni, Habibollah Esmaily, Maliheh Hasanzadeh Mofard

{"title":"Capecitabine-Enhanced Brachytherapy in Locally Advanced Cervical Cancer: A Phase II Non-Randomized Trial on Safety and Efficacy.","authors":"Fatemeh Homaei Shandiz, Soudeh Arastouei, Sare Hosseini, Indira Prasad Giri, Seyed Alireza Javadinia, Mahdiye Dayanni, Habibollah Esmaily, Maliheh Hasanzadeh Mofard","doi":"10.1080/07357907.2025.2493238","DOIUrl":"10.1080/07357907.2025.2493238","url":null,"abstract":"Aim: To evaluate the safety and efficacy of administering capecitabine concurrent with brachytherapy in advanced-stage cervical cancer.Methods: Eligible patients with FIGO stage IB2-IVA cervical cancer were enrolled in this phase II non-randomized trial. After external beam chemoradiotherapy (EBRT), patients received capecitabine alongside brachytherapy as radiosensitizer. The primary objective was to assess the tolerability of the combined regimen and its effect on one-year disease-free (DFS) and overall survival rates (OS).Results: Of the 69 patients completed treatment, 18 were enrolled as intervention group and 51 served as controls. Both groups were matched in terms of comorbidities, stage, and response to EBRT. Overall, concurrent capecitabine administration during brachytherapy was safe. At one-year follow-up, one death was recorded in each group, with recurrence rates of 16.7% in the intervention group and 19.6% in the control group. One-year DFS was 82% (95% CI: 54%-98%) in the intervention group and 87% (95% CI: 72%-94%) in the control group, while one-year OS was 93% (95% CI: 53%-98%) and 97% (95% CI: 85%-99%), respectively (for both p < 0.05).Conclusion: In conclusion, while capecitabine-augmented brachytherapy was demonstrated to be safe in patients with advanced cervical cancer, its addition did not yield significant improvements in DFS or OS.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"244-256"},"PeriodicalIF":1.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143966556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Challenges and Evolving Treatments in Desmoid Fibromatosis: A Single Institution Experience. 硬纤维瘤病的临床挑战和不断发展的治疗：单一机构的经验。

IF 1.8 4区医学

Cancer Investigation Pub Date : 2025-04-01 Epub Date: 2025-04-21 DOI: 10.1080/07357907.2025.2493240

Austin Yu, Zachary Butler, Lesly Honore, Gabrielle Unson, Matthew Demetrious, Steven Gitelis, Jordan Tasse, Alan T Blank

{"title":"Clinical Challenges and Evolving Treatments in Desmoid Fibromatosis: A Single Institution Experience.","authors":"Austin Yu, Zachary Butler, Lesly Honore, Gabrielle Unson, Matthew Demetrious, Steven Gitelis, Jordan Tasse, Alan T Blank","doi":"10.1080/07357907.2025.2493240","DOIUrl":"10.1080/07357907.2025.2493240","url":null,"abstract":"Desmoid tumor (DT), also known as desmoid fibromatosis, is a rare, locally proliferative tumor characterized by an overgrowth of myofibroblastic cells. Due to the varied clinical presentation of DT, there are a multitude of treatment options. This study provides our institutional experience in characterizing and treating DT as well as patient outcomes. A retrospective review was performed for 49 patients diagnosed with DT. Patient demographics, tumor characteristics, treatment characteristics, and tumor recurrence were reported. We reported our institution's treatment trends over time, relative risk analysis for surgery, as well as univariate analysis for recurrence. Thirty-seven patients received surgery with an overall recurrence rate of 29.7% (11/37). In total, ten patients received medical therapy including tamoxifen/sulindac (n = 7), nirogacestat (n = 1), and sorafenib (n = 2). One patient has been followed with active surveillance. Relative risk for surgery and tumor recurrence was not significantly correlated with race, gender, location, or large tumor size > 5 cm. Four patients treated with medical therapy experienced tumor reduction and symptomatic improvement. Management of DT includes many surgical and non-surgical options. We noted a similar recurrence rate in patients who received surgical treatment to what has been reported in the literature roughly 33%. We also noted effective tumor control in patients receiving medical therapy. As such, surgery can be utilized in situations with well-demarcated DT which can be removed en bloc, while utilizing medical therapy for highly invasive tumors.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"257-266"},"PeriodicalIF":1.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Early Colon Cancer Prediction from Histopathological Images Using Enhanced Deep Learning with Confidence Scoring. 使用增强深度学习和信心评分从组织病理学图像中预测早期结肠癌。

IF 1.8 4区医学

Cancer Investigation Pub Date : 2025-03-01 Epub Date: 2025-04-03 DOI: 10.1080/07357907.2025.2483302

V P Gladis Pushparathi, J Shajeena, T Kamalam, M Revathi

{"title":"Early Colon Cancer Prediction from Histopathological Images Using Enhanced Deep Learning with Confidence Scoring.","authors":"V P Gladis Pushparathi, J Shajeena, T Kamalam, M Revathi","doi":"10.1080/07357907.2025.2483302","DOIUrl":"10.1080/07357907.2025.2483302","url":null,"abstract":"Colon Cancer (CC) arises from abnormal cell growth in the colon, which severely impacts a person's health and quality of life. Detecting CC through histopathological images for early diagnosis offers substantial benefits in medical diagnostics. This study proposes NalexNet, a hybrid deep-learning classifier, to enhance classification accuracy and computational efficiency. The research methodology involves Vahadane stain normalization for preprocessing and Watershed segmentation for accurate tissue separation. The Teamwork Optimization Algorithm (TOA) is employed for optimal feature selection to reduce redundancy and improve classification performance. Furthermore, the NalexNet model is structured with convolutional layers and normal and reduction cells, ensuring efficient feature representation and high classification accuracy. Experimental results demonstrate that the proposed model achieves a precision of 99.9% and an accuracy of 99.5%, significantly outperforming existing models. This study contributes to the development of an automated and computationally efficient CC classification system, which has the potential for real-world clinical implementation, aiding pathologists in early and accurate diagnosis.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"205-223"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Phase I Study of the Naturally Occurring Bioactive, Opioid Growth Factor, in Patients with Unresectable Hepatocellular Cancer. 自然产生的生物活性阿片生长因子在不可切除肝细胞癌患者中的I期研究

IF 1.8 4区医学

Cancer Investigation Pub Date : 2025-03-01 Epub Date: 2025-04-08 DOI: 10.1080/07357907.2025.2484774

Eric T Kimchi, Jussuf T Kaifi, Yixing Jiang, Guangfu Li, Diego M Avella, Niraj J Gusani, Ian Schreibman, Peter Waybill, Patricia J McLaughlin, Ian S Zagon, Jill P Smith, Kevin F Staveley-O'Carroll

{"title":"A Phase I Study of the Naturally Occurring Bioactive, Opioid Growth Factor, in Patients with Unresectable Hepatocellular Cancer.","authors":"Eric T Kimchi, Jussuf T Kaifi, Yixing Jiang, Guangfu Li, Diego M Avella, Niraj J Gusani, Ian Schreibman, Peter Waybill, Patricia J McLaughlin, Ian S Zagon, Jill P Smith, Kevin F Staveley-O'Carroll","doi":"10.1080/07357907.2025.2484774","DOIUrl":"10.1080/07357907.2025.2484774","url":null,"abstract":"Hepatocellular cancer (HCC), one of the world's most deadly tumors, and its incidence in the US continues to rise. Surgical resection/transplantation offers the only hope for cure; however, many patients are not candidates and have limited therapeutic options. Opioid growth factor (OGF) is a naturally occurring bioactive endogenous pentapeptide that inhibits growth of human HCC cell lines in vitro by a receptor-mediated mechanism and inhibits progression of tumors in nude mice. Based on these preclinical studies, we conducted a phase I clinical trial with dose escalation (standard 3 + 3 protocol) of OGF to determine the maximum tolerated dose in HCC patients with concomitant liver disease (NCT00706576). Fifteen doses were administered to 14 patients with a maximum 300 µg/kg dose. No Grade 3 toxicities were encountered in the study group. This dose exceeds the maximum tolerated dose reached in our previous phase I pancreatic cancer trial. We conclude that OGF can be safely administered to patients with HCC and concomitant liver disease without significant toxicities up to a dose of 300 µg/kg. The result of this trial provides data on toxicity and the pharmacokinetics of OGF in patients with HCC and liver disease and lays the groundwork for additional studies.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"224-235"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143802602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 1.8 4区医学

Cancer Investigation Pub Date : 2025-03-01 Epub Date: 2025-04-07 DOI: 10.1080/07357907.2025.2481436

Mengdi Fu, Hao Wu, Peng Peng, Jinhui Wang, Dongyan Cao

{"title":"Metabolism-Related Programmed Cell Death: Unveiling Prognostic Biomarkers, Immune Checkpoints, and Therapeutic Strategies in Ovarian Cancer.","authors":"Mengdi Fu, Hao Wu, Peng Peng, Jinhui Wang, Dongyan Cao","doi":"10.1080/07357907.2025.2481436","DOIUrl":"10.1080/07357907.2025.2481436","url":null,"abstract":"Background: Ovarian cancer (OC), the gynecologic malignancy with the poorest prognosis, is driven by metabolic reprogramming and dysregulated programmed cell death (PCD). However, their interplay and prognostic significance remain inadequately understood.Methods: Transcriptomic data from OC patients and healthy controls (TCGA and GTEx) were analyzed to identify differentially expressed genes (DEGs) intersecting with metabolism-related (MRGs) and PCD-related genes (PCDRGs). Prognostic genes were determined using univariate Cox regression, LASSO, multivariate Cox regression, and stepwise analyses. Consensus clustering revealed enrichment differences, while a risk model and nomogram were developed for outcome prediction. Associations between prognostic genes, immune microenvironment, and drug sensitivity were also assessed.Results: A total of 166 candidate genes were identified, with PLA2G2D, LPCAT3, ARG1, PLA2G4A, and EXOSC3 emerging as significant prognostic markers. The risk model demonstrated marked survival differences, while the nomogram showed robust calibration for survival prediction. Differential immune cell infiltration was observed between risk groups. Additionally, Sinularin and Fulvestrant exhibited variable sensitivity, validated through molecular docking models.Conclusion: Metabolism-related PCD genes were identified as pivotal prognostic markers in OC, providing critical insights for prognostic evaluation and targeted therapy development.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"183-204"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Topical Curcumin for Prevention of Radiation-Induced Dermatitis: A Pilot Double‑Blind, Placebo‑Controlled Trial. 局部姜黄素预防辐射性皮炎：一项双盲安慰剂对照试验。

IF 1.8 4区医学

Cancer Investigation Pub Date : 2025-03-01 Epub Date: 2025-03-27 DOI: 10.1080/07357907.2025.2479542

Behrooz Heydari, Soudabe Sheikhalishahi, Farahnaz Hoseinzade, Masood Shabani, Vahid Ramezani, Fatemeh Saghafi

{"title":"Topical Curcumin for Prevention of Radiation-Induced Dermatitis: A Pilot Double‑Blind, Placebo‑Controlled Trial.","authors":"Behrooz Heydari, Soudabe Sheikhalishahi, Farahnaz Hoseinzade, Masood Shabani, Vahid Ramezani, Fatemeh Saghafi","doi":"10.1080/07357907.2025.2479542","DOIUrl":"10.1080/07357907.2025.2479542","url":null,"abstract":"Background: Radiation-induced dermatitis, a common radiotherapy (RT) complication, affects 95% of breast cancer patients, with 10% experiencing severe reactions. Despite advancements, radiation dermatitis remains a challenge, disrupting treatment schedules and compromising patients' quality of life. Exploring herbal compounds, particularly Curcumin, has shown promise in addressing radiation-induced dermatitis, with its non-toxic and anti-inflammatory properties offering the potential for clinical trials to prevent these reactions.Methods: This phase II randomized, double-blinded, placebo-controlled trial focused on adult females undergoing conventional fractionated RT. The main objective was to assess the efficacy of topical Curcumin in reducing the severity of radiation dermatitis.Results: During a five-month study, 52 breast cancer patients completed the research. Participants were divided into Curcumin and placebo groups. In the first week, a significant difference in redness (P-value = 0.001) and irritation (P-value = 0.017) was observed, with the Curcumin group showing lower percentages. This trend continued in the second, third, and fourth weeks (P-value = 0.001). No statistical difference was found in itching (P-value = 0.446), and the occurrence of dryness (P-value = 1.000) remained constant in both groups throughout the four weeks. In pain the differences were significant in the second, third, and fourth weeks (P-value = 0.001).Conclusion: The study highlights the success of a 2% Curcumin gel in reducing skin side effects during breast cancer radiation therapy, suggesting its potential to enhance patients' quality of life.Trial registration: IRCT20181208041882N3, 06/11/2020 (https://en.irct.ir/trial/49228).","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"173-182"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143718110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Validation of Local Versus Commercial Genomic Testing in Cancer: A Comparison of Tissue and Plasma Concordance. 本地与商业癌症基因组检测的临床验证：组织和血浆一致性的比较。

IF 1.8 4区医学

Cancer Investigation Pub Date : 2025-02-01 Epub Date: 2025-02-24 DOI: 10.1080/07357907.2025.2464684

Lucy G Faulkner, Lynne Howells, Susann Lehman, Caroline Cowley, Zahirah Sidat, Jacqui Shaw, Anne L Thomas

{"title":"Clinical Validation of Local Versus Commercial Genomic Testing in Cancer: A Comparison of Tissue and Plasma Concordance.","authors":"Lucy G Faulkner, Lynne Howells, Susann Lehman, Caroline Cowley, Zahirah Sidat, Jacqui Shaw, Anne L Thomas","doi":"10.1080/07357907.2025.2464684","DOIUrl":"10.1080/07357907.2025.2464684","url":null,"abstract":"Genomic sequencing of tumours improves patient outcomes through implementation of precision oncology. At present, genomic testing is mainly confined to research settings, with samples sent to biopharmaceutical companies for analysis. The ever-expanding catalogue approved of targeted therapies has created an urgent unmet need for local genomic testing facilities, to enable upscaling of testing. Here, we compare the outcomes of local (IonTorrent™) and commercial (Foundation Medicine) genomic testing collected from 30 cancer patients in from plasma and tissue samples. Overall concordance was high in both tissue (98%) and plasma (94.2%). Variants identified by both platforms had a strong correlation in variant allele frequencies (VAF%): plasma: r = 0.99 p < 0.0001, tissue: r = 0.91 p < 0.0001. However, numerous low VAF% variants resulted in low positive percentage agreement (tissue 78.8% plasma 16.1%) and positive predictive values (tissue 56.3% plasma 71.4%). Local sequencing demonstrated higher fidelity in detecting fusions but low fidelity in detecting indels. Overall, this study supports the use of local genomic testing for routine molecular diagnostics but highlights outstanding issues before widespread implementation. Processing of variants detected at low VAF% and the limit of detection of assays needs to be addressed. Construction of gene panels requires careful consideration, including incorporation of markers of genomic instability.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"119-140"},"PeriodicalIF":1.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exclusion of People Living with HIV in Aggressive B-Cell Non-Hodgkin Lymphoma Studies: A Cross-Sectional Analysis of Clinical Trials from 2014 to 2024. 在侵袭性b细胞非霍奇金淋巴瘤研究中排除艾滋病毒感染者：2014年至2024年临床试验的横断面分析

IF 1.8 4区医学

Cancer Investigation Pub Date : 2025-02-01 Epub Date: 2025-02-08 DOI: 10.1080/07357907.2025.2462568

Daniel J Olivieri, Ajay K Gopal, Thomas S Uldrick, Manoj P Menon

{"title":"Exclusion of People Living with HIV in Aggressive B-Cell Non-Hodgkin Lymphoma Studies: A Cross-Sectional Analysis of Clinical Trials from 2014 to 2024.","authors":"Daniel J Olivieri, Ajay K Gopal, Thomas S Uldrick, Manoj P Menon","doi":"10.1080/07357907.2025.2462568","DOIUrl":"10.1080/07357907.2025.2462568","url":null,"abstract":"Background: Human immunodeficiency virus is associated with the development of various aggressive non-Hodgkin B-cell lymphomas (NHL). Despite this, people living with HIV (PLWH) are often excluded from clinical trials. Here we analyze the change in clinical trial exclusion among PLWH resulting from multilateral advocacy efforts since 2017.Methods: We identified all US-based clinical trials with the keyword \"lymphoma\" with start dates between January 01, 2014 and January 04, 2025 using the publicly available NIH Clinical Trial Database (https://www.clinicaltrials.gov/). All studies with aggressive B-cell NHL subtypes were included. Regression models were performed to analyze descriptive factors.Results: 1,973 US-based clinical trials were captured, of which 945 met criteria for further analysis. PLWH were excluded from 59% pre-2018 versus 48% post-2018. After multivariate adjustment, NIH-funded trials (24% exclusion rate, p < 0.001), other funders (64% exclusion rate), and studies initiated post-2018 (48% exclusion rate, p < 0.001) were associated with inclusion, while CAR-T-related studies (62% exclusion rate, p < 0.05) were associated with exclusion.Conclusions: Likely partly due to advocacy from ASCO, NCI, and NCCN, there was a significant decrease in exclusion among PLWH in US-based NHL clinical trials. Future research should analyze the safety and efficacy of immunotherapy in PLWH to foster inclusion and reduce stigma among physicians and researchers.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"141-148"},"PeriodicalIF":1.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143373845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Search for Healthcare and Breast/Gynecological Cancer Prevention Among Brazilian Lesbian Cisgender Women. 搜索巴西女同性恋、顺性女性的保健和乳腺癌/妇科癌症预防。

IF 1.8 4区医学

Cancer Investigation Pub Date : 2025-02-01 Epub Date: 2025-01-27 DOI: 10.1080/07357907.2025.2457614

Carolina de Souza, Manoel Antônio Dos Santos

{"title":"Search for Healthcare and Breast/Gynecological Cancer Prevention Among Brazilian Lesbian Cisgender Women.","authors":"Carolina de Souza, Manoel Antônio Dos Santos","doi":"10.1080/07357907.2025.2457614","DOIUrl":"10.1080/07357907.2025.2457614","url":null,"abstract":"Although breast, cervical, endometrial, and ovarian cancers account for more than 43% of new cases in 2023 in Brazilian women, no national studies were found on the incidence, risk factors, and prevention of breast and gynecological neoplasms in lesbian women, causing the health needs of non-heterosexual women to go unnoticed by professionals. This study aims to identify and analyze the search for healthcare related to the prevention of breast/gynecological cancer among Brazilian lesbian cisgender women who have not had the disease. Seven lesbian women participated in this qualitative study. Semi-structured interviews were conducted and subsequently transcribed and analyzed following the reflexive thematic analysis approach and the theoretical framework of gender studies. Two thematic axes were constructed: gynecological appointments, which includes the subthemes follow-ups, types of exams, and struggles with the healthcare system, and meeting health professionals, which includes relationships with professionals, searching for professionals, discussing sexual orientation, and (un)preparedness. The participants in this study reported visiting a gynecologist at least once and doing preventive exams, although the frequency of these appointments varied for each woman. However, they highlighted that healthcare providers are not adequately prepared to address the needs of lesbian women and to talk about sexual orientation.","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"149-160"},"PeriodicalIF":1.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0